Aprea Therapeutics (APRE) Q4 2025 earnings summary

Executive summary

• Achieved early clinical proof-of-concept for WEE1 inhibitor APR-1051 in endometrial cancer with two partial responders in the ACESOT-1051 trial.

• Strengthened clinical team with appointment of a new Chief Medical Advisor to support next clinical development phase.

• Raised $8.7 million through private placements in late 2025 and early 2026, enhancing financial flexibility.

Financial highlights

• Cash and cash equivalents were $14.6 million as of December 31, 2025, down from $22.8 million at year-end 2024.

• Operating loss for Q4 2025 was $2.6 million, compared to $3.2 million in Q4 2024; full-year operating loss was $13.2 million, down from $14.3 million in 2024.

• Net loss for Q4 2025 was $2.5 million ($0.32 per share) versus $2.9 million ($0.49 per share) in Q4 2024; full-year net loss was $12.6 million ($1.93 per share) versus $13.0 million ($2.35 per share) in 2024.

• Grant revenues for 2025 were $0.3 million, down from $1.5 million in 2024.

Outlook and guidance

• Cash position, including January 2026 private placement, expected to fund operations into Q1 2027.

• Further updates from the ACESOT-1051 trial anticipated in Q2 2026.